The seminar discusses pediatric acute myeloid leukemia (AML), highlighting its poor outcomes despite advancements in understanding its biology and treatments. It reviews recent therapy updates, including new drug formulations and genetic risk classifications, while emphasizing the high relapse rates and limited options for affected children. The presentation underscores the necessity for further research and tailored treatment strategies to improve patient outcomes.